CROGNOC 100 MG INJ VIAL

About

Carboplatin is a widely utilized platinum-based alkylating agent in cancer chemotherapy, functioning by forming inter- and intra-strand DNA crosslinks. This crucial action inhibits DNA replication and transcription, ultimately leading to cell cycle arrest and programmed cell death (apoptosis) in rapidly dividing cancer cells. Compared to its predecessor, cisplatin, carboplatin offers a more favorable toxicity profile, particularly with reduced nephrotoxicity and neurotoxicity, although it is associated with greater myelosuppression. It is a cornerstone in the treatment of various solid tumors, including ovarian cancer, non-small cell lung cancer, small cell lung cancer, and head and neck cancer. Often administered intravenously as part of multi-drug chemotherapy regimens, carboplatin plays a significant role in achieving tumor regression and improving patient survival rates across a spectrum of malignancies.

Uses

• Ovarian Cancer
• Non-Small Cell Lung Cancer
• Small Cell Lung Cancer
• Head and Neck Cancer

Directions For Use

Administer intravenously by a qualified healthcare professional. Dosage is calculated based on AUC.

Benefits

• Effective against various solid tumors
• Less nephrotoxic than cisplatin
• Less neurotoxic than cisplatin
• Often used in combination regimens
• Induces tumor cell death
• Improves survival in certain cancers

Side Effects

• Myelosuppression (thrombocytopenia, leukopenia, anemia)
• Nausea
• Vomiting
• Peripheral neuropathy (less severe than cisplatin)
• Ototoxicity (less severe than cisplatin)
• Hypersensitivity reactions
• Fatigue
• Hair loss (alopecia)
• Electrolyte disturbances (hypomagnesemia, hypokalemia)
• Diarrhea
• Stomatitis

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may exacerbate gastrointestinal side effects or general malaise.
• Pregnancy - Contraindicated due to teratogenic effects; effective contraception is essential.
• Breastfeeding - Not recommended; discontinue breastfeeding during treatment.
• Liver - Use with caution in patients with hepatic impairment; monitor liver function.
• Kidney - Dose adjustment is crucial in patients with renal impairment to prevent severe myelosuppression.
• Lung - Rare cases of interstitial lung disease have been reported; monitor for respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.